Mahamaya Lifesciences Limited has scheduled a virtual investor and analyst meeting for August 07, 2026, at 4:00 PM IST. The company disclosed the schedule on August 04, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The event aims to provide investors with an opportunity to engage directly with senior management regarding the company’s operations and strategy.

The meeting will be conducted via video conferencing as a group session. Mahamaya Lifesciences explicitly stated that no unpublished price-sensitive information (UPSI) will be shared or discussed during the call. All interactions will be based strictly on publicly available information, ensuring compliance with regulatory standards for fair disclosure.

Meeting Details

Management Speakers

Senior leadership from Mahamaya Lifesciences will participate in the discussion:

• Krishnamurthy Ganesan, Managing Director
• Prashant Krishnamurthy, Executive Director & CFO

Investors and analysts can register for the meeting through the provided QR code or via the Orim Connect platform. The company noted that the meeting may be cancelled, rescheduled, or postponed due to exigencies involving the analysts, investors, or company management.

Regulatory Compliance

Pursuant to Regulation 46(2) of the Listing Regulations, the intimation regarding the investor meet has been uploaded to the company’s website at www.mahamayalifesciences.com . The disclosure was submitted to the Listing Compliance Department of BSE Limited, where the company is listed under Scrip Code 544611 on the BSE SME platform.

What This Means for Investors

This scheduled engagement allows stakeholders to seek clarity on recent developments without the risk of asymmetric information flow. By restricting discussions to public data, Mahamaya Lifesciences maintains transparency while adhering to SEBI guidelines. Participants should prepare questions focused on publicly reported financials and operational updates.

Mahamaya Lifesciences has accepted the resignation of Shilpi Bhardwaj as Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP). The departure is effective July 30, 2026, with Bhardwaj citing alternate career opportunities outside the organization as the reason for her exit. The company confirmed that there are no material reasons for her resignation other than those stated.

The Board of Directors approved the resignation on July 30, 2026. Bhardwaj submitted her resignation letter dated June 10, 2026, under the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the Companies Act, 2013. She will be relieved from her duties at the close of business hours on July 30, 2026.

Resignation Details

Bhardwaj confirmed in her resignation letter that she would extend all necessary assistance and cooperation to ensure a smooth handover of responsibilities during the notice period. The company disclosed the change pursuant to Regulation 30 read with Paragraph A, Part A of Schedule III of the SEBI Listing Regulations, 2015.

Krishnamurthy Ganesan, Managing Director of Mahamaya Lifesciences, signed the intimation to BSE Limited. The filing included Annexure A detailing the event and the resignation letter. No other material changes in key managerial personnel were reported alongside this announcement.